The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ARCT | -57.44% | -81.98% | -29.02% | -13% |
| S&P | +14.08% | +93.57% | +14.12% | +165% |
Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.
The company saw revenue decline and net losses rise in the second quarter.
Investors liked what they heard in its Q4 update.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $17.15M | -55.8% |
| Gross Profit | $23.71M | -47.4% |
| Gross Margin | 96.74% | -1.3% |
| Market Cap | $500.46M | -20.3% |
| Market Cap / Employee | $2.84M | 0.0% |
| Employees | 176 | -2.2% |
| Net Income | -$13.45M | -94.8% |
| EBITDA | -$10.78M | -504.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $235.36M | -19.4% |
| Accounts Receivable | $7.95M | -73.7% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $21.87M | -15.9% |
| Short Term Debt | $4.03M | 2.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -20.43% | -6.1% |
| Return On Invested Capital | -25.80% | 5.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$5.95M | 80.3% |
| Operating Free Cash Flow | -$5.95M | 80.1% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.76 | 1.19 | 1.51 | 2.17 | -9.79% |
| Price to Sales | 3.31 | 2.19 | 3.21 | 5.69 | 31.79% |
| Price to Tangible Book Value | 1.76 | 1.19 | 1.51 | 2.17 | -9.79% |
| Price to Free Cash Flow TTM | 86.43 | - | |||
| Enterprise Value to EBITDA | -295.02 | -3.92 | -9.10 | -26.69 | -86.98% |
| Free Cash Flow Yield | 1.2% | - | |||
| Return on Equity | -31.2% | -27.4% | -24.6% | -27.4% | 24.89% |
| Total Debt | $28.55M | $42.66M | $26.96M | $21.87M | -25.68% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
